Regeneron Pharmaceuticals Continue Higher Following a Mid-Day Report from Deutsche Bank
February 11, 2014 at 16:24 PM EST
Deutsche Bank released a mid-day report Tuesday on Regeneron Pharmaceuticals (NASDAQ: REGN ) in which the firm maintained its Buy rating and raised the price target from $375 to $410. In evaluating Regeneron, Deutsche Bank's Robyn Karnauskas noted the key take away from Regeneron's fourth quarter 2013 as being, "The